13F Holdings
中文EN

GMED GLOBUS MEDICAL INC

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1237831 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.4%
TTM net income YoY31.6%
TTM EPS YoY31.4%
Revenue 3-yr CAGR36.8%
Net income 3-yr CAGR52.3%

Margins

Gross margin69.1%
Operating margin21.6%
Net margin17.8%
FCF margin24.4%
EBITDA margin28.7%

Returns

ROE12.1%
ROA10.5%
ROIC (approx.)12.9%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets13.2%
Debt / equity0.00x
Current ratio4.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.66x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue5.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.94B$2.52B$1.57B$1.02B$958.10M
Cost of revenue$957.80M$1.04B$548.17M$263.73M$239.22M
Gross profit$1.98B$1.48B$1.02B$759.12M$718.88M
R&D expense$147.25M$163.75M$124.01M$73.02M$97.35M
SG&A expense$1.18B$981.36M$643.84M$432.12M$408.15M
Operating income$479.82M$165.99M$133.14M$227.95M$171.95M
Pretax income$605.07M$120.72M$165.39M$243.02M$180.41M
Income tax$67.20M$17.74M$42.52M$52.85M$31.22M
Net income$537.87M$102.98M$122.87M$190.17M$149.19M
EBITDA$756.66M$419.38M$278.67M$296.20M$241.82M
EPS (basic)3.980.761.091.891.48
EPS (diluted)3.920.751.071.851.44
Weighted avg. shares (diluted)137.06M137.86M114.63M102.64M103.62M
Banking
Net interest income—-$4.19M$20.13M$14.23M$9.30M
Balance sheet
Cash & equivalents$526.16M$784.44M$467.29M$150.47M$193.07M
Short-term investments$31.09M$105.62M$50.50M$295.59M$250.38M
Receivables$678.94M$557.70M$503.24M$213.25M$164.44M
Inventory$759.28M$659.23M$848.13M$298.98M$237.00M
Current assets$2.13B$2.18B$1.92B$983.34M$864.52M
PP&E, net$564.45M$561.91M$586.93M$243.73M$221.08M
Goodwill$1.44B$1.43B$1.43B$197.47M$179.71M
Intangibles$745.06M$795.12M$924.60M$63.57M$68.66M
Total assets$5.30B$5.25B$5.09B$2.08B$1.96B
Current liabilities$498.50M$855.91M$392.35M$159.20M$140.16M
Total liabilities$729.51M$1.07B$1.09B$229.75M$215.88M
Shareholders' equity$4.57B$4.18B$4.00B$1.85B$1.74B
Cash flow statement
Operating cash flow$753.45M$520.64M$243.50M$178.47M$276.27M
Capital expenditure$164.68M$115.43M$78.27M$74.05M$56.90M
Free cash flow$588.77M$405.21M$165.22M$104.42M$219.38M
Investing cash flow-$355.01M-$176.05M$302.97M-$110.36M-$375.94M
Financing cash flow-$679.16M-$27.70M-$231.82M-$109.96M$54.15M
Depreciation & amortization$276.84M$253.39M$145.53M$68.25M$69.87M
Stock-based compensation$49.78M$54.19M$52.74M$32.81M$30.59M
Share buybacks$300.45M$85.79M$225.56M$144.49M—

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.